$BEAT News

Last published 2w ago

2w agoBEATHeartBeam to Present Results of ALIGN-ACS Study for Heart Attack Assessment at TCT 2026 on November 1, 2026Business WireALIGN-ACS pilot study compared the HeartBeam 3D ECG technology to a standard 12-lead ECG for detection of acute coronary syndrome (ACS) Results will inform the design of HeartBeam’s planned U.S. pivotal study,
2w agoBEATHeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP)Business WireAcceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam’s heart attack assessment technologyTAP Pilot provides dedicated FDA advisors and early engagement with
3w agoBEATHEADSTART-ACS Completes Enrollment Ahead of Schedule, the Largest Heart Attack Detection Study to Date Using HeartBeam TechnologyBusiness WireHEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million people Data
3w agoBEATHeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk PatientsBusiness WireHeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium HeartBeam will lead the HEART-CHECK Study, one of the project’s 22
1mo agoBEATHeartBeam Receives FDA Breakthrough Device Designation for Heart Attack AssessmentBusiness WireDesignation recognizes the potential of HeartBeam’s 3D ECG technology to help physicians assess suspected heart attacks outside the hospitalBreakthrough status provides prioritized FDA interaction as HeartBeam advances
1mo agoBEATHeartBeam, Inc. Letter to ShareholdersBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today issued a letter to shareholders from its Executive Chairman Richard
3mo agoBEATHeartBeam Reports Second Quarter 2026 ResultsBusiness WireCompleted Enrollment in ALIGN-ACS Heart Attack Detection Pilot Study Ahead of Schedule; Full Results to be Presented at TCT 2026 Surpassed 50% Enrollment Ahead of Schedule in Indonesian Government-Supported
3mo agoBEATHeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern
4mo agoBEATHeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG DeviceBusiness WirePatent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities Acoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve
4mo agoBEATHeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of ScheduleBusiness WireAccelerated enrollment completion in ALIGN-ACS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at
4mo agoBEATHeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership TransitionBusiness WireCompany will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its
5mo agoBEATHeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at HomeBusiness WirePublication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific
6mo agoBEATHeartBeam Reports First Quarter 2026 ResultsBusiness WireSigned First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern
6mo agoBEATHeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the ClinicBusiness WireAmbulatory patch device designed to aid in detecting ischemia and complex arrythmias Targets a $2 billion market with established reimbursement; ischemia detection has potential to disrupt the patch market which is
6mo agoBEATHeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge PracticeBusiness WireLeading concierge practice Atelier Health, led by physicians affiliated with Cedars-Sinai, will now offer HeartBeam to its patients Opens up flagship sites across New York, Dallas, South Florida and Southern
6mo agoACRX ANIK AXGN BEAT+6TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 RevenuesGlobeNewswireMALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a
6mo agoBEATHeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time
6mo agoBEATHeartBeam Announces Closing of $10 Million Public Offering of Common StockBusiness WireOffering was led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company
7mo agoBEATHeartBeam Announces Pricing of $10 Million Public Offering of Common StockBusiness WireOffering is being led by HeartBeam's first commercial customer, ClearCardio™, the Company's executive leadership, board members, and existing investors HeartBeam, Inc. (NASDAQ:BEAT), a medical technology
7mo agoBEATHeartBeam Announces Proposed Public Offering of Common StockBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it is commencing an underwritten public offering of shares of
7mo agoBEAT HTFL HYPR GEHCHow Decentralized AI is Unlocking Value in Cardiac DiagnosticsPR NewswireUSANewsGroup.com News Commentary – Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the European...
8mo agoBEATHeartBeam Reports Fourth Quarter and Full Year 2025 ResultsBusiness WireHeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG
8mo agoBEATHeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the HomeBusiness WireAccelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk Combines Mount Sinai's world-class AI and clinical expertise
8mo agoBEATHeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear PatchBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and industry conferences
8mo agoBEATHeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot StudyBusiness WireHeartBeam's technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies key step
8mo agoBEATHeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time
8mo agoBEATHeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology MarketBusiness WireMarks HeartBeam's transition to commercial company Rapidly growing practice and highly engaged member population to enable broad adoption Enables efficient scaling of additional preventive cardiology and
10mo agoBEATHeartBeam to Attend JP Morgan 2026 Annual Healthcare ConferenceBusiness WireHeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key Initiatives in
11mo agoBEATHeartBeam Receives FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia AssessmentBusiness WireFDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam's Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients Anytime,
11mo agoBEATHeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software ApplicationBusiness WireCompany engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can address any
12mo agoBEATHeartBeam Reports Third Quarter 2025 ResultsBusiness WireCommercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is
1y agoBEATHeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13, 2025 at 4:30 p.m.
1y agoBEATHeartBeam Teams Up With HeartNexus to Deliver Cardiologist-Level ECG Insights Anytime, AnywhereBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced a partnership with HeartNexus, Inc., a network of
1y agoBEATHeartBeam's Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting ArrhythmiasBusiness WireNew study presented at HRX Live 2025 demonstrates continued advancement of company's AI program HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in classifying
1y agoBEATHeartBeam to Participate at Upcoming Industry and Investor Conferences, September 4-10, 2025Business WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will attend
1y agoBEATHeartBeam, Inc. (BEAT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoBEATHeartBeam Reports Second Quarter 2025 ResultsBusiness WireExecuting on Commercial Readiness Plans in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Engaged in Ongoing Productive Discussions with FDA Related to the
1y agoBEATHeartBeam Wins Industry Innovation Award for Advancing Remote Cardiac Care With Groundbreaking ECG TechnologyBusiness WireFDA-cleared technology makes clinical-grade ECG insights for arrhythmia assessment available outside of a medical facility HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac
1y agoBEATHeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025Business WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that Robert Eno, Chief Executive Officer, and Timothy
1y agoBEAT MDBHMDB Capital Holdings Provides First Quarter 2025 UpdateGlobeNewswireAddison, TX, May 21, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ:MDBH) ("MDB"), a public venture platform focused on launching category-leading disruptive technology companies, today provides an update
1y agoBEATHeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent PortfolioBusiness WireFirst patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the defensive and offensive moat around the company's core technology Second patent expands the
1y agoBEATHeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and GrowthBusiness WireBoard expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing
1y agoBEATHeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern
1y agoBEATHeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis TechnologyBusiness WireMilestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming
1y agoBEATHeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring InnovationBusiness WireCollaboration brings together two leaders in ambulatory ECG recording and analysis HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized
1y agoBEATHeartBeam Reports Fourth Quarter and Full Year 2024 ResultsBusiness WireReceived FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for
1y agoBEATHeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025Business WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will be
1y agoBEATHeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern TimeBusiness WireHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern
1y agoBEATHeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common StockBusiness WireAdditional gross proceeds of approximately $1.5 Million Follows successful closing of $10 million underwritten offering Funding is part of the Company's strategic plan focusing on key growth milestones and
1y agoBEATHeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common StockBusiness WireHeartBeam system was recently cleared by the U.S. Food and Drug Administration (FDA) for comprehensive arrhythmia assessment 510(k) application submitted to the FDA for the Company's groundbreaking 12-lead